<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969214</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/015213</org_study_id>
    <nct_id>NCT01969214</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea</brief_title>
  <official_title>Open Label Study to Assess the Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several
      studies demonstrating their efficacy, the investigators are conducting this study to look
      into the efficacy and safety of IQP-MM-101 in diarrhoea control.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (in hours) between the 1st intake of IQP-MM-101 and first formed or hard stool followed by a non watery stool</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (hours) from the first intake to the last watery stool</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stools</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of watery stools</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency and consistency</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients having recovered within a certain time period (defined as having achieved the primary efficacy endpoint)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated symptoms such as nausea, vomiting and abdominal pain</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time off from work</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of energy for &quot;everyday life&quot;</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of safety and efficacy by subjects and investigators</measure>
    <time_frame>72 hours</time_frame>
    <description>The subjects and investigators will evaluate independently the safety of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse events (AEs)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diarrhoea</condition>
  <arm_group>
    <arm_group_label>IQP-MM-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dissolve the effervescent tablets in half a glass of water,to be taken orally
1 tablet, 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQP-MM-101</intervention_name>
    <description>Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day</description>
    <arm_group_label>IQP-MM-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Good general health

          -  Acute diarrhoea episode defined as at least three watery stools per 24 hours over a
             period of 48 hours or less

          -  Acute diarrhoea of presumed infectious origin

          -  Patients with usually normal bowel movements (defecations) before onset of diarrhoea,
             that is, at least three normal stools per week and three or less normal stools per day

          -  Negative pregnancy test (ß HCG-test) for women with child bearing potential

          -  Written informed consent is a prerequisite for subject enrollment

        Exclusion Criteria:

          -  Known sensitivity to the ingredients of the device

          -  Fever &gt;38,5◦C

          -  Blood or pus in stools

          -  Dehydration requiring intravenous rehydration

          -  History of chronic diarrhoea (three or more loose or watery stools per day for at
             least 12 weeks, consecutive or not, in the preceding 12 months)

          -  Use of antidiarrhoeal agents over the month prior to baseline

          -  Diarrhoea possibly induced by antibiotics, laxative agents, thyroid hormones, or
             colchicine

          -  Irritable bowel syndrome

          -  Any other acute or chronic disease that could interfere with the evaluation of study
             device

          -  Females who are pregnant or lactating

          -  Subjects who have participated in another clinical trial in the 30 days before
             treatment period

          -  Inability to comply

          -  Presence of other factor(s) that, in the investigator's judgement, should preclude
             subject participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felix Alt</last_name>
    <phone>+49 30/40 00 81 50</phone>
    <email>falt@analyze-realize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 4, 2016</submitted>
    <returned>February 4, 2016</returned>
    <submitted>February 4, 2016</submitted>
    <returned>March 2, 2016</returned>
    <submitted>March 7, 2016</submitted>
    <returned>April 5, 2016</returned>
    <submitted>January 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

